Display options
Cite
Rakici H, Akdogan RA, Ayaz T, et al. Is There Any Advantage of Treating Partners in Helicobacter pylori Eradication?. Gastroenterol Res Pract. 2015;2015:706507doi: 10.1155/2015/706507.
Rakici, H., Akdogan, R. A., Ayaz, T., & Bedir, R. (2015). Is There Any Advantage of Treating Partners in Helicobacter pylori Eradication?. Gastroenterology research and practice, 2015706507. https://doi.org/10.1155/2015/706507
Rakici, Halil, et al. "Is There Any Advantage of Treating Partners in Helicobacter pylori Eradication?." Gastroenterology research and practice vol. 2015 (2015): 706507. doi: https://doi.org/10.1155/2015/706507
Rakici H, Akdogan RA, Ayaz T, Bedir R. Is There Any Advantage of Treating Partners in Helicobacter pylori Eradication?. Gastroenterol Res Pract. 2015;2015:706507. doi: 10.1155/2015/706507. Epub 2015 Mar 15. PMID: 25861262; PMCID: PMC4377513.
Copy Download .nbib Format: NLM
Share it on

Gastroenterol Res Pract. 2015;2015:706507. doi: 10.1155/2015/706507. Epub 2015 Mar 15.

Is There Any Advantage of Treating Partners in Helicobacter pylori Eradication?.

Gastroenterology research and practice

Halil Rakici, Remzi Adnan Akdogan, Teslime Ayaz, Recep Bedir

Affiliations

  1. Department of Gastroenterology, School of Medicine, Recep Tayyip Erdogan University, 53 100 Rize, Turkey.
  2. Department of Internal Medicine, School of Medicine, Recep Tayyip Erdogan University, 53 100 Rize, Turkey.
  3. Department of Pathology, School of Medicine, Recep Tayyip Erdogan University, 53 100 Rize, Turkey.

PMID: 25861262 PMCID: PMC4377513 DOI: 10.1155/2015/706507

Abstract

Aim. We designed this trial to find answers to the following questions. (1) Does the success rate decrease in a country where HP prevalence is high? (2) Can we provide benefit by simultaneously treating the partners of infected patients? Materials and Methods. The first group consisted of 102 HP-positive patients, and both the patients and their HP-positive partners were treated. The second group consisted of 104 HP-positive patients whose partners were HP-positive but only the patients were treated. The participants in both groups were treated with levofloxacin 500 mg daily, amoxicillin 1 g b.i.d, and lansoprazole 30 mg b.i.d (LAL) for ten days. Results. In the per-protocol analysis, the eradication success rate was found to be 92.2% (94/8) in the first group and 90.4% (94/10) in the second group. No statistically significant difference was found between the two groups (P > 0.05). Conclusions. With regard to the HP eradication rate, no difference was found between treating the HP-positive partners of HP-positive patients simultaneously and not treating them simultaneously. According to these results, we can say that reinfections between partners do not significantly contribute to the failure of eradication.

References

  1. Endoscopy. 2007 Nov;39(11):942-7 - PubMed
  2. Aliment Pharmacol Ther. 2003 Feb 15;17(4):553-60 - PubMed
  3. J Gastroenterol. 2012 Jun;47(6):641-6 - PubMed
  4. Am J Gastroenterol. 2003 Nov;98(11):2395-402 - PubMed
  5. Am J Gastroenterol. 2006 Mar;101(3):488-96 - PubMed
  6. Aliment Pharmacol Ther. 2010 May;31(10):1077-84 - PubMed
  7. Z Gastroenterol. 2002 Jun;40(6):383-7 - PubMed
  8. Gut. 2012 May;61(5):646-64 - PubMed
  9. Gut. 1996 Nov;39(5):768 - PubMed
  10. Chin Med J (Engl). 2014;127(3):568-73 - PubMed
  11. Helicobacter. 2013 Sep;18 Suppl 1:58-65 - PubMed
  12. Helicobacter. 2005;10 Suppl 1:1-4 - PubMed
  13. Helicobacter. 2012 Sep;17 Suppl 1:36-42 - PubMed
  14. J Clin Gastroenterol. 2000 Apr;30(3):337 - PubMed
  15. J Gastroenterol Hepatol. 1999 Jun;14(6):519-22 - PubMed
  16. Int J Food Microbiol. 2010 Mar 31;138(1-2):1-12 - PubMed
  17. Helicobacter. 2013 Apr;18(2):135-42 - PubMed
  18. Curr Pharm Des. 2014;20(28):4489-500 - PubMed
  19. J Antimicrob Chemother. 2012 Sep;67(9):2254-9 - PubMed
  20. Am J Gastroenterol. 2005 Sep;100(9):2083-99 - PubMed
  21. Helicobacter. 2006 Jun;11(3):168-72 - PubMed
  22. Epidemiol Rev. 2000;22(2):283-97 - PubMed
  23. Dig Dis Sci. 2014 Aug;59(8):1698-709 - PubMed
  24. Eur J Gastroenterol Hepatol. 2002 Aug;14(8):865-71 - PubMed

Publication Types